Tag - BEAT

Developments

HeartBeam reveals positive results of heart attack assessment study at TCT

HeartBeam (NASDAQ: BEAT) has revealed positive results today from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment presented by Graham Nichol, MD, MPH, FRCP(C), of the University of...

November 2, 2026

Developments

FDA clears HeartBeam’s cable-free, 12-lead ECG for at-home use

HeartBeam (NASDAQ: BEAT) has announced that the FDA has granted 510(k) clearance for its first-ever, cable-free, 12-lead electrocardiogram (ECG) synthesis software for the at-home assessment of arrhythmias. According to...

December 11, 2025

Developments

HeartBeam files 510(k) application with FDA for ECG software

HeartBeam (NASDAQ:BEAT) has announced the submission of a 510(K) application to the FDA for its 12-lead electrocardiogram (ECG) synthesis software, designed to analyze diverse cardiac rhythms and arrhythmias, leveraging...

January 30, 2025

Tag - BEAT

HeartBeam reveals positive results of heart attack assessment study at TCT

FDA clears HeartBeam’s cable-free, 12-lead ECG for at-home use

HeartBeam files 510(k) application with FDA for ECG software

Subscribe